Published in Int Immunol on October 31, 2007
Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res (2014) 1.52
The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov (2015) 1.09
TNF receptor-associated factor 5 is required for optimal T cell expansion and survival in response to infection. J Immunol (2008) 1.03
Adenoviral vector-based strategies for cancer therapy. Curr Drug ther (2009) 1.02
Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells. J Immunol (2012) 0.94
Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancer. Clin Dev Immunol (2012) 0.88
Transplantation tolerance and its outcome during infections and inflammation. Immunol Rev (2014) 0.86
Inter-ethnic differences in lymphocyte sensitivity to glucocorticoids reflect variation in transcriptional response. Pharmacogenomics J (2011) 0.86
Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study. J Immunother (2012) 0.85
Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44(+)CD62L(high) IL-7R(+) CTLs with up- and downregulation of anti- and pro-apoptosis genes. Cell Mol Immunol (2014) 0.82
Enhanced antitumor effects of a dendritic cell vaccine transfected with gastric cancer cell total RNA carrying the 4-1BBL gene in vitro. Exp Ther Med (2011) 0.79
Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse. Clin Dev Immunol (2013) 0.76
Natural Killer Cell Functional Activity After 4-1BB Costimulation. Inflammation (2015) 0.76
Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment. Front Immunol (2017) 0.75
Viral gene therapy strategies: from basic science to clinical application. J Pathol (2006) 1.88
Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol (2004) 1.54
Short-term hemodynamic effects of cardiac resynchronization therapy in patients with heart failure, a narrow QRS duration, and no dyssynchrony. Circulation (2009) 1.51
Vectors based on reducible polycations facilitate intracellular release of nucleic acids. J Gene Med (2003) 1.30
Structural and mechanistic studies of Escherichia coli nitroreductase with the antibiotic nitrofurazone. Reversed binding orientations in different redox states of the enzyme. J Biol Chem (2005) 1.16
A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Mol Ther (2009) 1.16
Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses. Mol Ther (2010) 1.02
Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954. J Mol Biol (2007) 0.96
Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. Cancer Res (2003) 0.94
Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs. Bioorg Med Chem Lett (2011) 0.91
4-1BBL costimulation retrieves CD28 expression in activated T cells. Cell Immunol (2009) 0.89
Left ventricular strain and untwist in hypertrophic cardiomyopathy: relation to exercise capacity. Am Heart J (2010) 0.87
Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954. Biochemistry (2009) 0.85
Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12. Cancer Immunol Immunother (2011) 0.83
Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy. J Med Chem (2003) 0.82
Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector. Int J Cancer (2003) 0.81
Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations. Biochem Pharmacol (2009) 0.79
Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation. J Med Chem (2006) 0.79
CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus. Mol Cancer (2010) 0.78
The nitroreductase/CB1954 enzyme-prodrug system. Methods Mol Med (2004) 0.78
Sarcoidosis presenting as complete heart block in a 45-year-old farmer: an aetiology not to miss. J R Soc Med (2013) 0.75
Synergistic anti-tumor effects of nitroreductase mutants and p53. J Cancer Res Ther (2014) 0.75
Adenovirus-mediated expression of dominant negative fibroblast growth factor (FGF) receptor 1 in thyroid cells blocks FGF effects and reduces goitrogenesis in mice. J Clin Endocrinol Metab (2003) 0.75
Preferential T cell expansion by artificial antigen presenting cells expressing 4-1BBL alone or in combination with CD80 or CD86. Iran J Immunol (2008) 0.75